Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Mergers & Acquisitions
Celgene to sell Otezla to Amgen in advance of being bought by Bristol-Myers
by Michael McCoy
August 30, 2019
| A version of this story appeared in
Volume 97, Issue 34
Celgene will sell the psoriasis treatment Otezla to Amgen for $13.4 billion in cash. The sale is intended to win US Federal Trade Commission clearance for Bristol-Myers Squibb’s $74 billion acquisition of Celgene, which was announced in January. After that deal was revealed, the FTC indicated that the combination of Otezla with a similar BMS drug in the late stages of development would be anticompetitive. The Otezla sale is contingent on the FTC’s approval of the Celgene-BMS deal.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter